These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

441 related items for PubMed ID: 16380617

  • 1. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders.
    Allen AJ, Kurlan RM, Gilbert DL, Coffey BJ, Linder SL, Lewis DW, Winner PK, Dunn DW, Dure LS, Sallee FR, Milton DR, Mintz MI, Ricardi RK, Erenberg G, Layton LL, Feldman PD, Kelsey DK, Spencer TJ.
    Neurology; 2005 Dec 27; 65(12):1941-9. PubMed ID: 16380617
    [Abstract] [Full Text] [Related]

  • 2. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome.
    Spencer TJ, Sallee FR, Gilbert DL, Dunn DW, McCracken JT, Coffey BJ, Budman CL, Ricardi RK, Leonard HL, Allen AJ, Milton DR, Feldman PD, Kelsey DK, Geller DA, Linder SL, Lewis DW, Winner PK, Kurlan RM, Mintz M.
    J Atten Disord; 2008 Jan 27; 11(4):470-81. PubMed ID: 17934184
    [Abstract] [Full Text] [Related]

  • 3. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G, Maschietto D, Bravaccio C, Calamoneri F, Masi G, Curatolo P, Besana D, Mancini F, Rossi A, Poole L, Escobar R, Zuddas A, LYCY Study Group.
    Eur Neuropsychopharmacol; 2009 Nov 27; 19(11):822-34. PubMed ID: 19716683
    [Abstract] [Full Text] [Related]

  • 4. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
    Bangs ME, Hazell P, Danckaerts M, Hoare P, Coghill DR, Wehmeier PM, Williams DW, Moore RJ, Levine L, Atomoxetine ADHD/ODD Study Group.
    Pediatrics; 2008 Feb 27; 121(2):e314-20. PubMed ID: 18245404
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.
    Wilens TE, Adler LA, Weiss MD, Michelson D, Ramsey JL, Moore RJ, Renard D, Brady KT, Trzepacz PT, Schuh LM, Ahrbecker LM, Levine LR, Atomoxetine ADHD/SUD Study Group.
    Drug Alcohol Depend; 2008 Jul 01; 96(1-2):145-54. PubMed ID: 18403134
    [Abstract] [Full Text] [Related]

  • 7. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.
    Adler LA, Liebowitz M, Kronenberger W, Qiao M, Rubin R, Hollandbeck M, Deldar A, Schuh K, Durell T.
    Depress Anxiety; 2009 Jul 01; 26(3):212-21. PubMed ID: 19194995
    [Abstract] [Full Text] [Related]

  • 8. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.
    Clin Ther; 2007 Jun 01; 29(6):1168-77. PubMed ID: 17692731
    [Abstract] [Full Text] [Related]

  • 9. Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.
    Newcorn JH, Spencer TJ, Biederman J, Milton DR, Michelson D.
    J Am Acad Child Adolesc Psychiatry; 2005 Mar 01; 44(3):240-8. PubMed ID: 15725968
    [Abstract] [Full Text] [Related]

  • 10. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.
    Wang Y, Zheng Y, Du Y, Song DH, Shin YJ, Cho SC, Kim BN, Ahn DH, Marquez-Caraveo ME, Gao H, Williams DW, Levine LR.
    Aust N Z J Psychiatry; 2007 Mar 01; 41(3):222-30. PubMed ID: 17464703
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis.
    Adler LA, Wilens T, Zhang S, Dittmann RW, D'Souza DN, Schuh L, Durell TM.
    Clin Ther; 2012 Feb 01; 34(2):363-73. PubMed ID: 22285724
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
    Spencer TJ, Abikoff HB, Connor DF, Biederman J, Pliszka SR, Boellner S, Read SC, Pratt R.
    Clin Ther; 2006 Mar 01; 28(3):402-18. PubMed ID: 16750455
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
    Biederman J, Swanson JM, Wigal SB, Kratochvil CJ, Boellner SW, Earl CQ, Jiang J, Greenhill L.
    Pediatrics; 2005 Dec 01; 116(6):e777-84. PubMed ID: 16322134
    [Abstract] [Full Text] [Related]

  • 16. Donepezil use in children and adolescents with tics and attention-deficit/hyperactivity disorder: an 18-week, single-center, dose-escalating, prospective, open-label study.
    Cubo E, Fernández Jaén A, Moreno C, Anaya B, González M, Kompoliti K.
    Clin Ther; 2008 Jan 01; 30(1):182-9. PubMed ID: 18343255
    [Abstract] [Full Text] [Related]

  • 17. An open-label, prospective study of guanfacine in children with ADHD and tic disorders.
    Boon-yasidhi V, Kim YS, Scahill L.
    J Med Assoc Thai; 2005 Nov 01; 88 Suppl 8():S156-62. PubMed ID: 16856436
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
    Biederman J, Wigal SB, Spencer TJ, McGough JJ, Mays DA.
    Clin Ther; 2006 Feb 01; 28(2):280-93. PubMed ID: 16678649
    [Abstract] [Full Text] [Related]

  • 20. Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment.
    Wernicke JF, Adler L, Spencer T, West SA, Allen AJ, Heiligenstein J, Milton D, Ruff D, Brown WJ, Kelsey D, Michelson D.
    J Clin Psychopharmacol; 2004 Feb 01; 24(1):30-5. PubMed ID: 14709944
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.